CJC-1295 is a peptide hormone composed of 30 amino acids. In the human body it works as an analogue of somatoliberin (a natural stimulator of growth hormone secretion). It acts on the nucleus of the anterior pituitary gland and stimulates the secretion of growth hormone. The substance binds to GHRH receptors, which belong to the group of G protein-coupled receptors. The CJC-1295 version of DAC (Drug Affinity Complex) binds to plasma proteins (albumin), resulting in a significant increase in duration of action, due to the addition of lysine bound to the non-peptide molecule DAC (the version without Il DAC lasts 30 minutes).
GHRH GROUP
The abbreviation GHRH stands for Growth Hormone Releasing Hormone or Somatoliberin. Somatotropin-releasing hormone, also known as somatotropin-releasing factor (GRF, GHRF) or somatocrinin, is a growth hormone-releasing hormone. It is a 44 amino acid peptide hormone produced in the hypothalamus.
Mechanism of action
Somatoliberin is released from the nerve endings of these arcuate neurons and is transported to the anterior pituitary gland, where stimulates the secretion of growth hormone by stimulating special receptors. GHRH is released in a pulsatile manner, stimulating a similar pulsatile release of growth hormone. Furthermore, somatoliberin also directly contributes to slow wave sleep.
The action of somatoliberin is opposite to the action of somatostatin (a hormone that inhibits growth hormone). Somatostatin is released from the neurosecretory nerve endings of periventricular somatostatin neurons and transported to the anterior pituitary gland, where it inhibits growth hormone secretion. Somatostatin and somatoliberin are secreted in turn, causing a more pulsatile secretion of growth hormone.
Pesticides of the GHRH group work only when the level of somatostatin in the blood is low or the activity of this hormone is minimal. And this happens only at a time when the level of growth in the blood increases after natural releases or after injections. It is possible, but rather difficult, to determine when endogenous growth hormone will be released into the blood and, accordingly, to adapt the injection of the GHRH peptide to it. Therefore, in practice, the following method is used: the stimulant of the GHRH group is injected after the stimulant of the GHRH group. Less oftenafter an injection of exogenous somatotropin.
GHRH peptides increase the level of endogenous growth hormone and this is followed by the positive effects inherent in growth hormone. This hormone plays a key role in regulating body composition. An important property of growth hormone is its powerful lipolytic effect. Administration of growth hormone to people with a deficiency reduces body fat mass and significantly increases lean mass. Growth hormone improves lipolysis directly by reducing the action of a number of lipogenic enzymes and indirectly by increasing the production of other lipolytic hormones such as catecholamines and glucagon, as well as by increasing the expression of adipocyte adrenoreceptors. In general, these effects lead to an increase in the utilization of body fat.
Growth hormone plays an important role as an anabolic agent in the connective tissue of human skeletal muscles and tendons, which provides the matrix for the transmission of force from individual muscle fibers to bones. Therefore, the strengthened connective tissue will give a stronger and more resistant muscle-tendon structure. For this reason, growth hormone is used by athletes to treat muscle and tendon injuries. Likewise, elevated levels of GH improve bone strength both directly and indirectly by increasing intestinal calcium absorption and serum vitamin D concentrations.
Purpose of Use
One One of the most popular effects of growth hormone is its effect on muscle anabolism. Growth hormone induces the absorption of glucose and amino acids and stimulates protein synthesis, possibly using energy derived from its lipolytic activity. Growth hormone leads to an increase in the level of the IGF-1 protein, which in turn also has a number of positive synergistic effects with growth hormone, such as burning fat, increasing muscle mass and strengthening bone structures and tendons. Reasons to consider using GHRH peptides may include increased fat loss, improved muscle gain, reduced cholesterol and triglyceride levels, and improved healing after injuries. Some substances from the GHRH group have successfully transitioned into the category of pharmacological drugs, but most are still in the research or clinical trial phase.
Advantages
- No negative impact on blood sugar levels
- Forms a natural pulsating character of growth hormone spikes in the blood
Effects< /b>
- Sustained increase in growth hormone and IGF-q levels
- Reduce visceral adipose tissue
- Reduce the total cholesterol and triglycerides in the blood
- Increased muscle mass
Side effects
- Facial redness and short-term pain at the injection site
- ArthralgiaPain that occurs in different joints of the musculoskeletal system
- Myalgia (is a syndrome characterized by pain to the muscles, ligaments, tendons and membranes of the fascia connective tissue of the muscles)
Tesamorelin, GRF (1-44)
Tesamorelin is a of the first growth hormone stimulants. Long ago, researchers discovered that the last 15 amino acids of the somatoliberin chain are useless, which is why sermorelin was created as a sequence of the first twenty-nine amino acids. But all 44 amino acids remained in the risamorelin chain, and a trans-3-hexonoyl group was also added to them. This was done to prolong the period of effectiveness of the drug: the period of its effective activity is not less than 4-5 hours. Tesamorelin is used very actively in medical practice like no other stimulator of growth hormone secretion. Even despite the fact that today there are more effective drugs in this group. The effectiveness of the manufacturer’s recommended daily dose (2 mg, if the drug is used alone) of tesamorelin is approximately equal to the effectiveness of three IU of synthetic growth hormone.
Sermorelin, GRF (1 -29)
Sermorelin is one of the few peptides that have successfully passed the clinical trial stage and have been actively used in medical practice. The structure of sermorelin corresponds to a fragment of somatoliberin (amino acids 1-29, which is reflected in the second name of this drug GRF (1-29). The action is completely similar to somatoliberin. It is short-lived, although the period of Effective activity lasts up to two hours and is not particularly potent, but when combined with GHRP group peptides it can significantly increase growth hormone levels.
Mod GRF (1-29)
It is actually sermorelin, but with a longer half-life. In 2005, researchers changed 4 amino acids in the structure of GRF in the second, eighth, fifteenth, and twenty-seventh positions. The resulting drug was called tetrasubstituted GRF (1 -29), i.e. GRF, in which 4 positions were replaced. In 2008, a researcher, known on the Internet by the nickname DatBtrue, proposed the modified name GRF (1-29) or Mod GRF (1-) for the drug. 29) to shorten the name by which it is known today. In our body, the path from the hypothalamus, where somatoliberin is synthesized, to the pituitary gland, where it should act, is very short. The hormone encounters no obstacles along the way, so the half-life of GRF (1-29) is only 5 minutes. Based on this, it became necessary to create a drug with a longer half-life. One solution is Mod GRF (1-29), which has a half-life of 30 minutes.
CJC-1295 with DAC
Based on Mod GRF (1-29) it is a drug was created with an even longer half-life, already calculated in days. This drug was named CJC1295. This drug has the same amino acid sequence as Mod GRF (1-29), but also contains the thirteenth amino acid, lysine, to which 3-maleimidopropionic acid is linked. This complex was called DAC (drug affinity complex). Subsequently, the Mod GRF (1-29) became known as the CJC-1295 without DAC or simply CJC1295, and the real CJC-1295 was called the CJC-1295 DAC. CJC-1295 is a very interesting drug that gives a good effect for a long period of time: in experiments it was used without interruption for up to six months or even more. Furthermore: the emissions of your own growth hormone still have the same pulsating nature, that is, they are completely natural, only stronger.
Application scheme
Almost all drugs from the GHRH group they have a very short half-life, calculated in minutes. it’s true, the period of actual activity is slightly longer, but it still doesn’t exceed a couple of hours. Therefore, the frequency of injections should be at least 3-4 per day. The group includes a drug with a very long period of activity CJC 1295 DAC, injections of which can be given twice a week.
Combination with other drugs
GHRH drugs are not usually used alone, but are often used in combination with a GHRP class peptide such as GHRP-2, GHRP-6, hexarelin, or ipamorelin. Examples of use are 100 mcg of Mod GRF 1-29 taken concurrently with 100 mcg of GHRP-6 or ipamorelin. This combination is synergistic. GHRP stimulates the GH release pulse and GHRP amplifies it. The dosage in combination with GHRP should be around 100 micrograms. The dosage of CJC 1295 DAC should be 100 mcg (1 mg) twice a week.
How to prepare a solution
To prepare a solution for injection you take a syringe already containing a diluent and injected into a vial containing a lyophilized powder. Tilt the vial so that the needle touches the wall of the vial. Avoid injecting the diluent directly into the lyophilized powder. The solvent should flow slowly down the wall of the bottle (don’t fill it all at once and take your time). Once all of the diluent has been added to the paprtide vial, mix gently (but do not shake or shake the vial) until the lyophilized powder has dissolved and a clear liquid remains. The medicine is now ready for use.
Never mix one peptide with another in the same syringe. This creates the risk that the fragile peptide molecules will be destroyed.
Application
- The injection can be subcutaneous, intramuscular, depending on personal preference.< /li>
Storage
- The resulting solution can be stored for about 21 days in the refrigerator at a temperature of 2-8°C . The storage time increases if the solution was prepared using bacteriostatic water.
Reviews
There are no reviews yet.